Regeneron Pharmaceuticals REGN Other intangible assets—net
Other intangible assets—net at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.
The official record: Regeneron Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Regeneron Pharmaceuticals's other intangible assets—net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Regeneron Pharmaceuticals's other intangible assets—net?
- Regeneron Pharmaceuticals (REGN) reported other intangible assets—net of $1.29B in Q1 2026.
- How has Regeneron Pharmaceuticals's other intangible assets—net changed year-over-year?
- Regeneron Pharmaceuticals's other intangible assets—net increased by 10.3% year-over-year, from $1.17B to $1.29B.
- What is the long-term trend for Regeneron Pharmaceuticals's other intangible assets—net?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's other intangible assets—net has grown at a 270.1% compound annual growth rate (CAGR), from $6.7M to $1.26B.
- What does other intangible assets—net mean?
- The net value of non-physical assets like patents, licenses, and trademarks.
- How do you interpret other intangible assets—net?
- Higher values suggest a strong pipeline or portfolio of protected intellectual property, though they require monitoring for impairment.
- How does other intangible assets—net compare across companies?
- Highly significant in the pharmaceutical industry due to the reliance on patent-protected drug portfolios.